Morbidity and mortality of patients with diabetic neuropathy treated with pathogenetically oriented alpha-lipoic acid versus symptomatic pharmacotherapies – A nationwide database analysis from Hungary

Abstract

AimsDiabetic neuropathy is associated with increased risk of morbidity and all-cause mortality. It is unclear whether these outcomes differ in patients with diabetic neuropathy treated with pathogenetically oriented vs symptomatic pharmacotherapies. MethodsWe performed a retrospective (2009–2019) database analysis of patients treated with pathogenetically oriented alpha-lipoic acid (ALA) or symptomatic pharmacotherapies for diabetic neuropathy. We investigated clinical outcomes in propensity score matched patients in Hungary. Changes in hazard ratios and annualized event rates were assessed and sensitivity analyses performed. ResultsHazard ratios favored treatment with ALA vs symptomatic pharmacotherapies regarding acute myocardial infarction (HR 0.73, 95% CI: 0.60–0.89, p = 0.0016), stroke (HR 0.71, 95% CI: 0.62–0.82, p < 0.0001), hospitalization for heart failure (HR 0.72, 95% CI: 0.66–0.78, p < 0.0001), cancer events (HR 0.83, 95% CI: 0.76–0.92, p = 0.0002) and all-cause mortality (HR 0.55, 95% CI: 0.49–0.61, p < 0.0001), but not for lower limb amputation (HR 1.05, 95% CI: 0.89–1.25, p = 0.5455). This association was supported by results of evaluating annual event rates and sensitivity analyses. ConclusionsThis retrospective database analysis revealed a lower occurrence of cardio- and cerebrovascular morbidity, cancer events and all-cause mortality in patients with diabetic neuropathy treated with pathogenetically oriented ALA vs symptomatic pharmacotherapies. This hypothesis-generating result requires further investigations.